Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06174818
Other study ID # Z-2021102
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 17, 2022
Est. completion date June 23, 2022

Study information

Verified date December 2023
Source Ziekenhuis Oost-Limburg
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

With the Pulsed Radiofrequency treatment (PRF) Of the Gasserian ganglion for tRigeminal nEuralgia: a retroSpective Study (PROGRESS) the objective is to document the outcome of PRF (Pulsed Radiofrequency treatment) for patients with TN (Trigeminal Neuralgia), unresponsive to conservative treatment.


Description:

Primary objective: To determine the proportion of patients in which PRF (pulsed radiofrequency) of the Gasserian ganglion for trigeminal neuralgia (TN) provides acute pain relief of at least 50% on the GPE (Global perceived effect) score (six weeks after treatment) Secondary objectives: - To determine the duration during which PRF of the Gasserian ganglion for trigeminal neuralgia provides a reduction of at least 50% on the GPE (Grade Point Equivalent) score.


Recruitment information / eligibility

Status Completed
Enrollment 85
Est. completion date June 23, 2022
Est. primary completion date June 23, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Patients with trigeminal neuralgia who underwent their first PRF of the Gasserian ganglion between 01/09/2013 and 31/08/2021 Exclusion Criteria: - None

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
PRF
Pulsed Radiofrequency Current of the Gasserian Ganglion

Locations

Country Name City State
Belgium ZOL Ziekenhuis Oost-Limburg Genk Limburg

Sponsors (1)

Lead Sponsor Collaborator
Ziekenhuis Oost-Limburg

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary GPE <50% To determine the proportion of patients in which PRF (pulsed radiofrequency) of the Gasserian ganglion for trigeminal neuralgia (TN) provides acute pain relief of at least 50% on the GPE (Global perceived effect) score (six weeks after treatment) Six weeks after treatment
Secondary Duration of GPE <50% To determine the duration during which PRF of the Gasserian ganglion for trigeminal neuralgia provides a reduction of at least 50% on the GPE (Grade Point Equivalent) score. This will be assessed six weeks post procedure and will be followed-up until definitive or possible relapse of neuralgia, assessed up to 48 months. From six weeks post procedure until definitive or possible relapse of neuralgia, assessed up to 48 months.
See also
  Status Clinical Trial Phase
Completed NCT03778177 - Neurophysiologic Signatures of Trigeminal Neuralgia Pain N/A
Completed NCT02951221 - New Formulation and Food Effect Study of BIIB074 Phase 1